These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33581698)

  • 21. Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.
    Holme PA; Tjønnfjord GE
    Haemophilia; 2019 Jan; 25(1):54-59. PubMed ID: 30394617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
    Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
    Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
    Mancuso ME; Fischer K; Santagostino E; Oldenburg J; Platokouki H; Königs C; Escuriola-Ettingshausen C; Rivard GE; Cid AR; Carcao M; Ljung R; Petrini P; Altisent C; Kenet G; Liesner R; Kurnik K; Auerswald G; Chambost H; Mäkipernaa A; Molinari AC; Williams M; van den Berg HM;
    Thromb Haemost; 2017 Dec; 117(12):2274-2282. PubMed ID: 29212115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simoctocog alfa for the treatment of hemophilia A.
    Morfini M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
    Delavenne X; Dargaud Y; Ollier E; Négrier C
    Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
    Romanov V; Marcucci M; Cheng J; Thabane L; Iorio A
    Thromb Haemost; 2015 Jul; 114(1):56-64. PubMed ID: 26017627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.